T cell-engaging bispecific antibodies (TCEs) are engineered molecules designed to bring cytotoxic T cells into proximity with tumor cells, triggering a targeted, antigen-dependent immune attack.

In a recent study published in the journal Frontiers in Immunology, researchers investigate the impact of dietary antigens in regulating small intestinal tumors. Despite being the most common type of ...

The bispecific antibodies market offers promising opportunities due to its rising application in personalized medicine for ...

Dr. Vadim Jucaud's lab at the Terasaki Institute has introduced a new organ-on-a-chip platform that recapitulates ...

EVM14, an mRNA cancer vaccine, received FDA clearance for investigational new drug application, advancing Everest's mRNA technology to global clinical trials. Preclinical studies showed EVM14 induces ...

IRVINE, Calif., Oct. 9, 2025 /PRNewswire/ -- GlyTR Therapeutics, a biotech company pioneering development of glycan-targeting cancer immunotherapies, announced the publication of its foundational ...